Copyright investors
In a welcome move, Novartis ADR (NVS) saw its Relative Strength Rating rise from 65 to 72 on Wednesday. This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to the rest of the market. Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Novartis ADR can continue to show renewed price strength and clear that threshold. While the stock is not near an ideal entry right now, see if it goes on to form and break out from a proper consolidation. Novartis ADR showed 9% EPS growth last quarter. Revenue rose 9%. The company holds the No. 4 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health (PAHC) is the top-ranked stock within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
